Commentary: Prevent a legal Catch-22 that could push thousands of generic drugs off the market
by Michael A. Carrier, Charles Duan and S. Sean Tu, Los Angeles Times
Sep 26, 2022
3 minutes
Carvedilol could be the poster child for how to lower drug prices. Since 2007, more than 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which cost 2 cents a dose compared with $4.81 for the brand-name product. Patents on the drug Coreg, dating back to 1978, have long expired, enabling these price-saving generics.
Yet this year, a federal jury deemed one generic carvedilol maker in violation of a patent to the tune of $235
You’re reading a preview, subscribe to read more.
Start your free 30 days